Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia

Clinical Cardiology

Volumn 22, Issue 1, 1999, Pages 25-28

  Iliadis, Elias A ^a   Rosenson, Robert S ^a,b  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fibric acid derivative; HMG CoA reductase inhibitor; Mixed hyperlipidemia; Myopathy; Statin

Indexed keywords

CHOLESTEROL; CREATINE KINASE; CREATININE; ESTROGEN; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; IMMUNOPRECIPITATION; MALE; MYOPATHY;

EID: 0032959122     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960220110     Document Type: Article

References (22)

1. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. J Am Med Assoc 1990;264:71-75
2. Rosenson RS, Frauenheim WA: Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 1994;74:499-500
3. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
4. Reaven P, Witzum JL: Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988;109:597-598
5. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG: Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80:608-613
6. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J Am Med Assoc 1996;275:128-133
7. Slaughter RL, Edwards DJ: Recent advances: The cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-624
8. Transon C, Leemann T, Dayer P: In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-215
9. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M: Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 1997;25:321-331
10. Yang BB, Hounslow NJ, Sedman AJ, Forgue ST: Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine. J Clin Pharmacol 1996;36:356-360
11. East C, Alivizatos PA, Grundy SM, Jones PH, Farmer JA: Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318:47-48
12. Meier C, Stey C, Brack T, Maggiorini M, Risti B, Krahenbuehl S: Rhabdomyolysis in patients treated with simvastatin and cyclosporin: Role of the hepatic cytochrome P450 enzyme system activity. Schweiz Med Wochenschr 1995;125:1342-1346
13. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, Young JB: Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. J Am Med Assoc 1988;260:239-241
14. Spach DH, Bauwens JE, Clark CD, Burke WG: Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154:213-215
15. Lees RS, Lees AM: Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Mud 1995;333:664-665
16. Jacobson RH, Wang P, Glueck CJ: Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. J Am Med Assoc 1997;277:296-297
17. U.S. Food and Drug Administration: FDA Talk Paper: Warning Labeling Changes for New Heart Drug Posicor. December 19, 1997;T97-65:1-4
18. Glueck CJ, Oakes N, Speirs J, Tracy T, Lang J: Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992;70:1-9
19. Rosenson RS: Gemfibrozil-lovastatin associated myalgia (letter). Am J Cardiol 1993;71:497
20. 12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 1995;27:2397-2402
21. Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlsson A, Linden T, Miettinen T, Odman B, Olofsson SO, Saarinen I, Sipila R, Sjostrom P, Kron B, Vanhanen H, Wright I: Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94:13-20
22. Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM: Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Ann Intern Med 1996;125:529-540